This is a promotional poster produced and fully funded by Bayer plc for UK healthcare professionals only. Prescribing information and adverse event reporting information for EYLEA® (aflibercept) 2 mg and EYLEA 8 mg can be accessed via the link or QR code located at the bottom of this document.

EYLEA® 8mg
(aflibercept 114.3mg/mL, solution for injection)

Global EYLEA® (aflibercept) 8 mg real-world evidence

Real-world outcomes in treatment-naïve patients with nAMD

Data from the IRIS Registry and Vestrum Health Retina database

nAMD

These data are from real patients. Individual results may vary.

Study design:

- From the IRIS Registry and Vestrum database, **58,638 and 23,338 patients**, respectively, received EYLEA 8 mg on the index date.* After applying the eligibility criteria, **4,417 patients from IRIS and 2,445 patients from Vestrum** were included in the final cohorts
- Treatment intervals were assessed in eyes with **≥2 injections during the initial phase† followed by ≥1 additional injection**
- Change in BCVA was assessed in eyes with data available at the index date and 90 ± 30 days after the index date*
- Safety parameters were not assessed in this analysis

Patient demographics

	IRIS Registry	Vestrum database
Patients in final cohort, N	4,417	2,445
Mean age, years	80.3	80.7
Female, %	62	63
Fellow eye treated on the index date, n	521	201

Extended treatment intervals with EYLEA 8 mg

Change in interval over time‡





After the initial dosing phase, patients achieved **extended treatment intervals with EYLEA 8 mg**

Vision outcomes with EYLEA 8 mg

Proportion of eyes gaining ≥5 ETDRS letters§

Change in BCVA over time§

No safety parameters were assessed in this analysis

Please see the EYLEA 8 mg Summary of Product Characteristics for full details of the safety profile.

*The index date was the date of the first EYLEA 8 mg injection. †First three injections or 90 days, whichever occurred first. ‡Treatment intervals were estimated during the initial dosing phase (i.e. first three injections or 90 days, whichever occurred first) and after initial dosing phase. Treatment intervals were assessed in eyes with ≥2 injections during the initial dosing phase, and in eyes with ≥1 injection after initial dosing phase. §Includes eyes with BCVA available at the index date and 90 ± 30 days after the index date.

Abbreviations:

BCVA, best corrected visual acuity; **ETDRS**, Early Treatment Diabetic Retinopathy Study; **nAMD**, neovascular age-related macular degeneration; **SD**, standard deviation.

Reference:

Ali FS *et al*. Presented at the Annual Scientific Meeting of The Retina Society 2025; Chicago, IL, USA, 10–13 September 2025.

May 2026 | PP-EYL_8mg-GB-1047

Prescribing information and adverse event reporting information for EYLEA® (aflibercept) is available via the QR code on the right.
Either click **here** or scan the QR code for prescribing information and adverse event reporting information.
For direct access to this prescribing information, please ensure your device's browser settings have automatic PDF download enabled.